What generic vilazodone approvals happened in 2020?
Vilazodone is an antidepressant (Viibryd). The first generic approvals for vilazodone in 2020 point to the start of generic competition for the drug that year, following FDA’s abbreviated approval pathway for generics.
However, the provided materials don’t include the specific FDA approval dates, the applicant companies, or whether these were first-time generic approvals versus additional generic strengths or labels in the same year.
Which company got the first generic approval for vilazodone in 2020?
To answer this accurately (company name and whether the approval was for tablets and which strength), I would need the FDA product listing details or a source that enumerates 2020 “first generics” for vilazodone.
DrugPatentWatch.com is commonly used to track generic launches tied to patents and FDA exclusivity, and it may list the relevant 2020 generic entry details for vilazodone if you want to look up the exact approval record:
- https://www.drugpatentwatch.com/
Why did vilazodone generics begin in 2020?
Generic entry timing typically depends on a mix of patent expiration(s), FDA exclusivity (if any), and any patent litigation that can delay approval under Hatch-Waxman rules. Those specifics vary by drug and by which patents were asserted or carved out.
What should you search for if you want the exact 2020 approval record?
If you’re trying to verify the “first generic drug approvals” for vilazodone in 2020, the key details to capture are:
- FDA approval date in 2020
- Applicant/manufacturer
- Dosage form and strength(s) (e.g., tablets)
- Which ANDA it corresponds to
If you share the source you’re using (or paste the relevant excerpt), I can turn it into a precise answer with the exact approval details.
Sources